Skip to main content
Premium Trial:

Request an Annual Quote

Oxford GlycoSciences' New CIO Will Spearhead Bioinformatics Charge

Premium

OXFORD, UK--Oxford GlycoSciences last month appointed Andrew Lyall to the position of chief information officer. Lyall formerly led research efforts in bioinformatics at Glaxo Wellcome as its head of advanced technology and informatics. At Glyco-Sciences he will be responsible for leading and expanding bioinformatics activities. Lyall holds a doctorate in bioinformatics from the University of Edinburgh and serves on a number of UK and international government and academic committees dealing with the emerging issues of bioinformatics and scientific computing.

GlycoSciences' CEO Michael Kranda remarked that "drug discovery, development, and commercialization are being transformed by new data- intensive technologies such as genomics and proteomics. But managing the data explosion and mining it for new therapeutic opportunities and diagnostics has resulted in a bottleneck which requires the development of advanced bioinformatics." Kranda added that he believes Lyall's expertise provides GlycoSciences with a competitive advantage as the company exploits its proteomics technology platform.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.